- PackSize
- 50ug/100ug
- Target
- IL-31
- Reactivity
- Dog
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Caninized
- Isotype
- IgG2-Kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- IL-31, Interleukin-31, IL31
- Species
- --
- Gene ID-1
- C7G0W1
- Uniprot
- --
- Background
- Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.<br>• The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037<br/>• IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760<br/>• Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401<br/>• A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353<br/>• Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036<br/>• Nemolizumab: First Approval., PMID:35834124<br/>• Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249<br/>• The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566<br/>• Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098<br/>• Targeting Interleukin-31 in Prurigo., PMID:37888922<br/>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --